# PRostate Olaparib Real World Evidence Study

> **NCT06031805** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 300 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06031805
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-11
- **Primary completion:** 2028-10-13
- **Final completion:** 2028-10-13
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031805, "PRostate Olaparib Real World Evidence Study". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06031805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*